clinical trial · NCT07239596
Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase2·recruiting·n = 139
Advanced Renal Cell CarcinomaSHR-8068；Adebrelimab ；BevacizumabSHR-8068；Adebrelimab ；HS-10516SHR-8068； Adebrelimab ； Bevacizumab ；HRS-10516
brief summary
This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma
started
Jan 6, 2026
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Mar 16, 2026
official title
An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination With Adebrelimab and Other Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol